These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Metabolic consequences of genetic heterogeneity of lipoprotein composition (lipoprotein heterogeneity). Brunzell JD; Chait A; Albers JJ; Foster DM; Failor RA; Bierman EL Am Heart J; 1987 Feb; 113(2 Pt 2):583-8. PubMed ID: 3812212 [TBL] [Abstract][Full Text] [Related]
5. Is familial combined hyperlipidaemia a genetic disorder of adipose tissue? Arner P Curr Opin Lipidol; 1997 Apr; 8(2):89-94. PubMed ID: 9183546 [TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein metabolism: a stable-isotope approach. Halliday D; Venkatesan S; Pacy P Am J Clin Nutr; 1993 May; 57(5 Suppl):726S-730S; discussion 730S-731S. PubMed ID: 8475890 [TBL] [Abstract][Full Text] [Related]
7. Comparison of apolipoprotein C-II-deficient triacylglycerol-rich lipoproteins and trioleoylglycerol/phosphatidylcholine-stabilized particles as substrates for lipoprotein lipase. Jackson RL; Tajima S; Yamamura T; Yokoyama S; Yamamoto A Biochim Biophys Acta; 1986 Feb; 875(2):211-9. PubMed ID: 3942763 [TBL] [Abstract][Full Text] [Related]
8. Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro. A possible pathophysiologic explanation for familial combined hyperlipidemia. Williams KJ; Petrie KA; Brocia RW; Swenson TL J Clin Invest; 1991 Oct; 88(4):1300-6. PubMed ID: 1918380 [TBL] [Abstract][Full Text] [Related]
9. Glycosylation of lipoproteins: chemistry and biological implications. Flückiger R Monogr Atheroscler; 1985; 13():53-62. PubMed ID: 3911059 [No Abstract] [Full Text] [Related]
10. Familial combined hyperlipidaemia: use of stable isotopes to demonstrate overproduction of very low-density lipoprotein apolipoprotein B by the liver. Cortner JA; Coates PM; Bennett MJ; Cryer DR; Le NA J Inherit Metab Dis; 1991; 14(6):915-22. PubMed ID: 1779650 [TBL] [Abstract][Full Text] [Related]
11. Tissue lipoprotein lipase activity and its action in lipoprotein metabolism. Cryer A Int J Biochem; 1981; 13(5):525-41. PubMed ID: 7016622 [No Abstract] [Full Text] [Related]
12. Metabolism of plasma low density lipoproteins in familial combined hyperlipidaemia: effect of acipimox therapy. Ericsson S; Eriksson M; Berglund L; Angelin B J Intern Med; 1992 Oct; 232(4):313-20. PubMed ID: 1402634 [TBL] [Abstract][Full Text] [Related]
13. Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. Ellis KL; Hooper AJ; Burnett JR; Watts GF Nat Rev Endocrinol; 2016 Aug; 12(8):467-84. PubMed ID: 27199287 [TBL] [Abstract][Full Text] [Related]
14. The roles of C-apolipoproteins in the metabolism of triglyceride-rich lipoproteins. Reckless JP; Stocks J; Holdsworth G Clin Sci (Lond); 1982 Feb; 62(2):125-9. PubMed ID: 7053911 [No Abstract] [Full Text] [Related]
15. Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia. Schonfeld G; Aguilar-Salina C; Elias N Am J Cardiol; 1998 Feb; 81(4A):43B-46B. PubMed ID: 9526813 [TBL] [Abstract][Full Text] [Related]
16. Kinetic bases of the primary hyperlipidaemias: studies of apolipoprotein B turnover in genetically defined subjects. Janus ED; Nicoll AM; Turner PR; Magill P; Lewis B Eur J Clin Invest; 1980 Apr; 10(2 Pt 1):161-72. PubMed ID: 6780364 [TBL] [Abstract][Full Text] [Related]
17. Low density lipoprotein metabolism in familial combined hyperlipidemia and familial hypercholesterolemia: kinetic analysis using an integrated model. Chait A; Foster DM; Albers JJ; Failor RA; Brunzell JD Metabolism; 1986 Aug; 35(8):697-704. PubMed ID: 3736410 [TBL] [Abstract][Full Text] [Related]
18. Absence of cholesteryl ester transfer protein-mediated cholesteryl ester mass transfer from high-density lipoprotein to low-density lipoprotein particles is a major feature of combined hyperlipidaemia. Guérin M; Bruckert E; Dolphin PJ; Chapman MJ Eur J Clin Invest; 1996 Jun; 26(6):485-94. PubMed ID: 8817163 [TBL] [Abstract][Full Text] [Related]
19. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition. Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607 [TBL] [Abstract][Full Text] [Related]
20. Increased hepatic lipase activity and increased direct removal of very-low-density lipoprotein remnants in Watanabe heritable hyperlipidaemic (WHHL) rabbits treated with ethinyl oestradiol. Demacker PN; Mol MJ; Stalenhoef AF Biochem J; 1990 Dec; 272(3):647-51. PubMed ID: 2268292 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]